ERBB2 and breast carcinoma: The approved HER2-targeted therapies for HER2-positive breast cancer include two antibodies (trastuzumab and pertuzumab), an antibody-drug conjugate (ado-trastuzumab emtansine), and a small molecule kinase inhibitor (lapatinib).